Semper Paratus Acquisition Long Term Debt 2022-2025 | TVGN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Semper Paratus Acquisition long term debt from 2022 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Semper Paratus Acquisition long term debt from 2022 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.4B
Amgen (AMGN)	$163.2B
Gilead Sciences (GILD)	$142.1B
Vertex Pharmaceuticals (VRTX)	$120.3B
Bristol Myers Squibb (BMY)	$95.4B
CSL (CSLLY)	$86B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$43.1B
Argenex SE (ARGX)	$36.6B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21B
Insmed (INSM)	$19.9B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$17.2B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.5B
Moderna (MRNA)	$12.6B
QIAGEN (QGEN)	$11.4B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9.1B
Exact Sciences (EXAS)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.5B